Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DFD-01 is a novel topical formulation of betamethasone dipropionate, specifically as a 0.05% emollient spray or lotion, developed for the treatment of mild to moderate plaque psoriasis. It is classified as a mid-potency corticosteroid and was designed to optimize skin penetration while minimizing systemic absorption and side effects typical of higher potency steroids[1][2][4]. The mechanism of action involves agonism at the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects in psoriatic lesions[5][7]. Clinical studies have shown that DFD-01 provides efficacy comparable to superpotent corticosteroids (such as Diprolene) but with an improved safety profile suitable for longer-term use[1][2][8]. The vehicle formulation also enhances skin barrier function and flexibility[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate spray 0.05%.